Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates...

Descripción completa

Detalles Bibliográficos
Autores principales: Shurrab, Farah M., Al-Sadeq, Duaa W., Abou-Saleh, Haissam, Al-Dewik, Nader, Elsharafi, Amira E., Hamaydeh, Fatima M., Halawa, Bushra Y. Abo, Jamaleddin, Tala M., Hameed, Huda M. Abdul, Nizamuddin, Parveen B., Amanullah, Fathima Humaira, Daas, Hanin I., Abu-Raddad, Laith J., Nasrallah, Gheyath K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877530/
https://www.ncbi.nlm.nih.gov/pubmed/35214650
http://dx.doi.org/10.3390/vaccines10020191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877530/
https://www.ncbi.nlm.nih.gov/pubmed/35214650
http://dx.doi.org/10.3390/vaccines10020191

Ejemplares similares